- NYSEAMERICAN:IBIO fell 0.49% to close out a rocky week for the small-cap biotech stock.
- IBIO continues to remain behind the bigger names in the industry when it comes to developing a vaccine.
- Even as the news of President Trump’s positive COVID diagnosis, investors had little interest in IBIO.
The great race for the coronavirus vaccine this year has brought the biotech and pharmaceutical industries into the investing limelight. As the big pharma juggernauts like Pfizer (NYSE:PFE), AstraZeneca (NASDAQ:AZN), and Moderna (NASDAQ:MRNA) continue to steal the headlines as they move closer to a successful vaccine candidate, tiny micro-cap biotech firms like iBioPharma have also received attention from investors. Shares have traded between $0.05 and $7.45 this year, although the 50-day and 200-day moving averages are right around the $2.05 range.
Where does IBIO rank amongst companies vying to win Operation Warp Speed? Not very high right now. Many of the larger names have moved well into Phase 3 of clinical trials while IBIO struggles to move along with its own plant-based candidates. One thing most analysts do agree on is that IBIO could have a potential game-changer on its hands with its FastPharming technology. Successful candidate or not, FastPharming can be used to produce COVID-19 vaccines at a rapid rate which may be necessary once successful candidates are chosen.
IBIO stock forecast
The current price levels of IBIO may be tempting to some bargain investors who want to take a shot at the COVID-19 vaccine play from a manufacturing angle. While it remains a longshot that IBIO-201 will be selected by countries as a widely used coronavirus vaccine, IBIO can easily make up for this with a high volume of vaccine and vaccine component production.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD holds above 0.6500 in thin trading
The Australian Dollar managed to recover ground against its American rival after AUD/USD fell to 0.6484. The upbeat tone of Wall Street underpinned the Aussie despite broad US Dollar strength and tepid Australian data.
EUR/USD comfortable below 1.0800 lower lows at sight
The EUR/USD pair lost ground on Thursday and settled near a fresh March low of 1.0774. Strong US data and hawkish Fed speakers comments lead the way ahead of the release of the US PCE Price Index on Friday.
Gold price finishes Thursday’s session set to reach new all-time highs
Gold price rallied during the North American session on Thursday and hit a new all-time high of $2,225 in the mid-North American session. Precious metal prices are trending higher even though US Treasury yields are advancing, underpinning the Greenback.
Bitcoin price extends retreat from $69K as old whales shift their holdings to new whales
Bitcoin price continues to move further away from the $69,000 threshold, gaining ground as BTC bulls hope for a retest of the $73,777 peak. This is because of the general assumption that clearing this blockade would set the tone for a reach higher, marking a new all-time high.
Bears have been standing before a steamroller so far this year
Despite a pushback on rate cuts from Christopher Waller, and what was supposed to be cautious trading sentiment ahead of critical US inflation data released later on Friday, the S&P 500 rose on Thursday, marking its best first-quarter performance in five years.